Usefulness of XXXX as first-line chemotherapy for metastatic extramammary @entity4261 .

@entity1 @entity5 @entity4261 @entity3 @entity1205
UNASSIGNED: In invasive extramammary @entity4261 (EMPD), distant @entity3 may develop and the condition may become fatal; however, no standardized treatment has been established. Although based on only a few cases, several chemotherapy regimens were reported to be promising. We conducted a multicenter, retrospective study to evaluate the efficacy of @entity1205 for metastatic EMPD. We retrospectively collected data on 18 metastatic EMPD @entity1 treated using @entity1205 from 1998 to 2012 in 12 institutes in Japan. The following clinical data were collected: @entity5 response, time to progression, overall survival and adverse effects. Of those, three @entity1 treated combined with S-1, one @entity1 treated with weekly schedule and one @entity1 treated combined with radiotherapy were excluded from the further analysis. All 13 @entity1 received monthly @entity1205 as the first-line treatment. The average number of treatment cycles was 9.1. Among the 12 @entity1 with a confirmed response, seven (58%) showed a partial response, three (25%) stable disease and two (17%) progressive disease. The disease control rate (partial response + stable disease) was as high as 83%. The time to progression and median overall survival were 7.1 and 16.6 months, respectively. The 1-year overall survival rate determined by the Kaplan-Meier method was 75.0%. All adverse effects were manageable and no treatment-related deaths were observed. The high disease control rate and overall survival shown by this study suggest that first-line use of @entity1205 may be a promising treatment for metastatic EMPD. A prospective clinical trial is required to confirm our results.
